✦ LIBER ✦

A phase I study of sulofenur in refractory pediatric malignant solid tumors

✍ Scribed by Charles B. Pratt; Laura C. Bowman; Neyssa Marina; Alberto Pappo; Loraine Avery; Xiaolong Luo; William H. Meyer

Book ID: 110591283
Publisher: Springer US
Year: 1995
Tongue: English
Weight: 349 KB
Volume: 13
Category: Article
ISSN: 0167-6997
DOI: 10.1007/bf02614222

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase I study of acivicin in refractor

A Phase I study of acivicin in refractory pediatric solid tumors

✍ Sylvain Baruchel; Mark Bernstein; V. Michael Whitehead; Susan Devine; Beverly Be 📂 Article 📅 1995 🏛 Springer US 🌐 English ⚖ 444 KB

A phase I trial of fazarabine in refract

A phase I trial of fazarabine in refractory pediatric solid tumors

✍ Mark L. Bernstein; V. Michael Whitehead; Holcombe Grier; Ron Dubowy; Vita Land; 📂 Article 📅 1993 🏛 Springer US 🌐 English ⚖ 289 KB

Phase I study of DMP 840 in pediatric pa

Phase I study of DMP 840 in pediatric patients with refractory solid tumors

✍ Joyce Thompson; Charles B. Pratt; Clinton F. Stewart; Loraine Avery; Laura Bowma 📂 Article 📅 1998 🏛 Springer US 🌐 English ⚖ 81 KB

Ifosfamide in pediatric malignant solid

Ifosfamide in pediatric malignant solid tumors

✍ C. B. Pratt; E. C. Douglass; E. L. Etcubanas; M. P. Goren; A. A. Green; F. A. Ha 📂 Article 📅 1989 🏛 Springer 🌐 English ⚖ 438 KB

Phase I study of fotemustine in pediatri

Phase I study of fotemustine in pediatric patients with refractory brain tumors

✍ Darren R. Hargrave; Eric Bouffet; Janet Gammon; Nauman Tariq; Ron M. Grant; Sylv 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB 👁 1 views

## Abstract ## BACKGROUND Fotemustine is a nitrosourea with theoretic and preclinical advantages over the original analogs, carmustine and lomustine, in the treatment of brain tumors. This is the first pediatric Phase I study of fotemustine. ## METHODS Patients younger than 21 with recurrent/res

Phase I trial of trimetrexate in pediatr

Phase I trial of trimetrexate in pediatric solid tumors: A pediatric oncology group study

✍ Pappo, Alberto S. ;Vats, Tribhawan ;Williams, Thomas E. ;Bernstein, Mark ;Kamen, 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 283 KB

## Abstract Trimetrexate (TMTX), a lipophilic antifol, was evaluated in a Pediatric Oncology Group (POG) Phase I trial in children with refractory solid tumors. TMTX was administered intravenously daily × 5 every three weeks. Starting dose was 6.4 mg/m^2^/day. Dose was escalated by 20% until the ma